CavoGene LifeSciences

CavoGene LifeSciences is a biotechnology company committed to individuals worldwide who are impacted by various neurodegenerative diseases. CavoGene is dedicated to the discovery, development and commercialization of novel gene therapies that are neuroprotective, restore motor neuron function, attenuate memory loss and increase synaptic neuroplasticity. Its lead therapy candidate, SynCav1, is in development for the company’s first clinical indication, Amyotrophic Lateral Sclerosis (ALS).